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Highlights Lay summary
 The rarer HBV genotype A (vs. E) is associated with
a higher risk of HCC (odds ratio 5.2).
 A genotype-independent deletion hotspot was
found in the preS2 domain (preS2D38–55).
 PreS2D38–55 was significantly associated with HCC
and is an independent risk factor.https://doi.org/10.1016/j.jhepr.2020.100144Although HBV-related liver disease is highly prevalent
in sub-Saharan Africa, the associated virological
characteristics are poorly studied. Using clinical data
from African patients chronically infected with HBV,
an assessment of the virological variability (genotypes
and mutations) and exposure to AFB1, a toxin often
contaminating food, was carried out. Our results show
that HBV genotypes, the presence of a highly preva-
lent mutant form of HBV, and AFB1 exposure
contribute to the high liver cancer risk in this
population.
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Background & Aims: Although HBV is a major cause of death in Africa, its genetic variability has been poorly documented.
This study aimed to address whether HBV genotype and surface gene variants are associated with HBV-related liver disease in
The Gambia.
Methods: We conducted a case-control study nested in the Prevention of Liver Fibrosis and Cancer in Africa programme.
Consecutive treatment-naive patients with chronic HBV infection and detectable viral load were recruited: 211 controls with
no significant liver disease and 91 cases (56 cirrhosis and 35 HCC cases). HBV genotypes and surface gene variants were
determined by Sanger sequencing or next-generation sequencing (NGS) in serum DNA. Aflatoxin B1 (AFB1)-specific codon
249 TP53 mutation was determined by NGS in circulating cell-free plasma DNA.
Results: In phylogenetic analysis, 85% of individuals carried HBV genotype E, 14% genotype A, and 1% A/E recombinant viruses.
Surface gene variants were more frequently observed in cases (43% and 57% in cirrhosis and HCC cases, respectively) than
controls (25%; p <0.001), with preS2 deletions between nucleotides 38–55 (preS2D38–55) being the main genetic variant
detected. In multivariable analysis, HBeAg seropositivity, low HBsAg levels, and HDV seropositivity were significantly asso-
ciated with cirrhosis and HCC, whilst older age, higher viral load, genotype A, preS2D38–55, and AFB1 exposure were only
associated with HCC. There was a multiplicative joint effect of preS2D38–55 variants with HBeAg seropositivity (odds ratio
[OR] 43.1 [10.4–177.7]), high viral load >2,000 IU/ml (OR 22.7 [8.0–64.9]), HBsAg levels <10,000 IU/ml (OR 19.0 [5.5–65.3]),
and AFB1 exposure (OR 29.3 [3.7–230.4]) on HCC risk.
Conclusions: This study identified a hotspot for HBV preS2 deletions as a strong independent factor for HCC in The Gambia,
with HBV genotypes and AFB1 exposure contributing to the high liver cancer risk.
© 2020 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL). This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Worldwide, 248 million individuals are positive for HBsAg, with
the highest prevalence (>8%) found in sub-Saharan Africa
(SSA).1 Chronic infection with HBV is a major cause of cirrhosis
and accounts for more than a half of the global 770,000 HCC
cases.2Keywords: Aflatoxin B1; Africa; Carcinogenesis; Cirrhosis; Genotype; Hepatitis B
virus; Hepatocellular carcinoma; PreS deletion.
Received 27 April 2020; received in revised form 25 June 2020; accepted 2 July 2020;
available online XXX
† Equally contributing authors.
* Corresponding author. Address: INSERM U1052, CNRS UMR5286, Centre de
Recherche en Cancérologie de Lyon Université Claude Bernard, 151 cours Albert
Thomas, Lyon, France.
E-mail address: Isabelle.chemin@inserm.fr (I. Chemin).The natural history of chronic HBV infection involves
complex viral-host interactions, and the development of
HBV-related HCC might be influenced by HBV genotypes and
genetic variants that emerge during chronic infection. Ten
genotypes (from A to J) exist based on a 7.5% nucleotide
divergence that cluster geographically and can be distin-
guished by surface gene sequencing.3,4 For instance, geno-
type A is found in North America, Europe, South Africa, and
India, whereas genotype E is predominant in West Africa.
Links have been suggested between the genotypes, trans-
mission routes, and impacts on clinical outcome.5 However,
these associations have not been completely elucidated
worldwide, particularly for the rarer HBV genotypes A and E
circulating in SSA.
Research ArticleHBV genetic variants have been reported in the 3.2 kb HBV
genome that encodes the viral polymerase, surface (preS/S),
precore/core, and X proteins.6 This includes base substitutions,
deletions, or insertions, which can emerge naturally during
chronic infection caused by error-prone viral replication. They
can persist as a dominant population during liver disease pro-
gression, modifying disease severity and cancer risk. For
instance, preS deletions reported in longitudinal and cross-
sectional studies conducted in Europe and Asia7 are generally
associated with liver disease progression and could promote
immune escape.8
HBV-associated HCC risk can also be modified by aflatoxin B1
(AFB1) exposure. This food contaminant is a class 1 human
carcinogen found in SSA and China, and may multiplicatively
amplify the effect of chronic HBV infection on HCC risk.9 The
molecular hallmark of AFB1-induced liver carcinogenesis is the
TP53 tumour suppressor gene codon 249 AGG>AGT mutation
(p53R249S), with its presence in circulating cell-free (cf)DNA
isolated from blood components considered as a surrogate
biomarker of AFB1 exposure.10
In The Gambia, West Africa, previous studies found that the
risk of HBV-related HCC is elevated in chronic HBV carriers with
high viral load,11 positive HBeAg,11 coinfected with HCV12 or
HDV,13 and previous exposure to AFB1.14 However, the impact of
HBV genotypes and variants has not been elucidated yet.
Therefore, to address this research gap, we conducted a case-
control study nested in the Prevention of Liver Fibrosis and
Cancer in Africa (PROLIFICA; www.prolifica.africa) programme15
in The Gambia.
Materials and methods
Study population
We investigated 302 treatment-naive HBsAg-positive patients
with detectable viral load consecutively enrolled in the PRO-
LIFICA programme from December 2012 to June 2015 (Fig. S1).
They were identified as HBsAg positive through either
community-based HBV screening15 or referral to the PROLIFICA
liver clinic for a suspected chronic liver disease.16
All patients had a standardised comprehensive liver assess-
ment, including physical examination, fasting liver stiffness
measurement (LSM) using FibroScan® (Echosens, Paris, France),
abdominal ultrasound with Doppler, liver function tests, and
virological investigations (including HDV, HCV, and HIV serol-
ogies), as described previously.15 Cirrhosis was diagnosed using
an LSM cut-off (9.5 kPa) previously validated in this population,17
or histologically or clinically in case of decompensated cirrhosis.
HCC cases were either identified histopathologically or clinically
if they fulfilled at least 2 of the following criteria: focal liver
lesion >−2 cm consistent with HCC by ultrasound; alpha-
fetoprotein (AFP) levels >−200 ng/ml; and cirrhosis.
16
Controls were defined as HBsAg-positive patients without
cirrhosis or HCC. The study was approved by The Gambia Gov-
ernment/MRC Joint Ethics Committee (SCC 1266) and conducted
according to the guidelines of the Declaration of Helsinki. Ethical
approval was granted by the institutional ethics committees, and
all participants gave informed consent.
Viral DNA extraction, PCR, and sequencing
Viral DNA extracted from patient sera (200 ll) using the
QIAamp® DNA Mini Kit (QIAGEN, Hilden, Germany) was used toJHEP Reports 2020PCR amplify the preS1/preS2/S gene before bidirectional Sanger
sequencing (GenBank submission ID 2208379).18,19 First-round
PCR was performed in 25 ll containing 5 ll HBV DNA and
the F8-50-ATTTGCATACTCTTTGGAAGGC-30 and R5-50-AAAGCC-
CAAAAGACCCACAAT-30 primers. Then, 1 ll of this product was
used in a nested PCR (primers F3-5ʹ-CGCCTCATTTTGTGGGTCAC-
3ʹ and R8 5ʹ-CTTTGACAAACTTTCCAATCAAT-3ʹ) resulting in 1.4 kb
(approximate) fragment. PCR products were checked on 1%
agarose gels and purified using QIAquick® PCR Purification Kit
(QIAGEN). The SeqScapeTM Software version 3.0 (Thermo Fisher
Scientific, Waltham, MA, USA) was used to join contigs with
respect to the reference HBV genotype C AB014360. The Multiple
Alignment using Fast Fourier Transform programme20 was
used for alignments and CLC Sequence Viewer 8 (QIAGEN Bio-
informatics) for mutation observation. Sequence logos were
generated using an online application.21
Genotyping and phylogenetic tree
Genotypes and recombinants were determined using the
jumping profile hidden Markov model.22 A/E recombinants were
cut at the break point and analysed separately (Fig. S2). Three
sequences were discarded from the data set (N-terminal of
EG7151, EG7194, and EG7190) because of their very short length
(<50 nt) leading to a set of 304 HBV S gene sequences from 302
individuals. Four S gene sequences of HBV genotype C
(AB014360), B (AB010289), D (AB048701), and F (AB036905)
have been added as external references.6 The sequences have
been aligned using MACSE version 2.03 (default parameters),23
and the resulting alignment was trimmed using BMGE version
1.024 (option -t CODON). The phylogenetic tree was inferred with
PhyML version 3.125 using the GTR+G4 evolutionary model
proposed by ModelFinder,26 according to the Bayesian informa-
tion criterion. The branch robustness was measured using the
non-parametric bootstrap procedure implemented in PhyML
(100 replicates of the original alignment). The inferred tree was
rooted by HBV genotype F sequence and visualised using Inter-
active Tree Of Life.27
AFB1 assessment by isolation of circulating cfDNA and
p53R249S fragment amplification
Circulating cfDNA was isolated from plasma (600 ll) of 117 pa-
tients, using the QIAamp® Circulating Nucleic Acid Kit (QIAGEN),
quantified using the Quant-iTTM PicoGreen® dsDNA Assay (Mo-
lecular Probes/Invitrogen), and used to PCR amplify a TP53
fragment covering codon 249 (Supplementary Methods and
materials).
Next-generation sequencing analysis by Ion Torrent
technology
The NEBNext® Fast DNA Library Prep Set for Ion Torrent® kit
(New England Biolabs) was used for TP53 mutation analysis
(Supplementary Methods and materials). The same protocol was
used to analyse the preS1/preS2/S amplicon. Purified barcoded
libraries were sequenced on Ion Torrent ProtonTM systems
(Thermo Fisher Scientific). The accuracy and detection threshold
and read error rate for the p53R249S mutation were determined
using genomic DNA from p53R249S homozygous PLCPRF5 cells
diluted into human wild-type (WT) DNA. For HBV sequences, the
detection limits for variant sequences were estimated at 2% with
a coverage of 10,000 reads.2vol. 2 j 100144
Table 1. Characteristics of the HBsAg-positive controls, cirrhosis cases, and HCC cases (n = 302).
Controls (n = 211) Cirrhosis cases (n = 56) HCC cases (n = 35) p value
Male 156 (74) 47 (84) 25 (71) 0.3
Median age (years) 33 (29–39) 36 (27–42) 40 (32–48) 0.03
Born in rural area 146 (69) 37 (66) 23 (66) 0.9
Family history of liver cancer 11 (5) 1 (2) 2 (6) 0.5
Ever drunk alcohol 11 (5) 6 (11) 3 (9) 0.3
Obesity 15 (7) 2 (4) 0 0.2
Median LSM (kPa) 5.3 (4.4–6.7) 15.9 (10.3–27.7) 75 (46.4–75) <0.001
Median ALT (IU/L) 27 (21–33) 39 (26–61) 65 (47–107) <0.001
Median AST (IU/L) 30 (26–38) 52 (33–102) 351 (195–429) <0.001
Median GGT (IU/L) 27 (21–39) 58 (36–100) 363 (201–624) <0.001
Median ALP (IU/L) 84 (69–106) 129 (85–182) 365 (261–452) <0.001
Median total bilirubin (mg/dl) 0.6 (0.5–0.9) 0.8 (0.6–2.1) 2.0 (1.2–5.5) <0.001
Median albumin (g/ml) 4.3 (4.0–4.5) 4.0 (2.9–4.3) 3.1 (2.8–3.3) <0.001
Median creatinine (mg/dl) 0.89 (0.76–1.03) 0.86 (0.71–0.98) 0.71 (0.60–1.11) 0.1
Median platelets (109 cells/L) 199 (156–251) 118 (81–174) 208 (143–329) <0.001
Median AFP (ng/ml) 4.2 (2.5–6.5) 13.4 (7.8–58.0) 1,559.0 (167.9–6,172.0) <0.001
HBeAg seropositivity 18 (8.5) 17 (30.9) 14 (40.0) <0.001
Median HBV DNA (log10 IU/ml) 2.7 (2.2–3.3) 4.0 (2.3–5.9) 5.2 (3.2–6.3) <0.001
Median HBsAg (log10 IU/ml) 4.1 (3.8–4.4) 3.7 (3.3–3.9) 3.6 (3.2–4.0) <0.001
Genotype <0.001
E 188 (89) 48 (86) 20 (57)
A 23 (11) 7 (12) 12 (34)
A and E 0 1 (2) 3 (9)
HBV mutations <0.001
Wild type 159 (75) 32 (57) 15 (43)
Other mutation 11 (5) 2 (4) 1 (3)
PreS2D38–55 41 (20) 22 (39) 19 (54)
Positive anti-HCV 0 2 (4) 3 (9) 0.001
Positive anti-HDV 1 (1) 4 (7) 5 (17) <0.001
Positive anti-HIV= 4 (2) 2 (4) 0 0.5
AFB1 exposure, n (%)a
No 60 (81) 22 (73) 6 (46) 0.03
Yes 14 (19) 8 (27) 7 (54)
Median allelic fraction in those positive for AFB1 (IQR) 0.009 (0.003–0.224) 0.039 (0.002–0.342) 0.332 (0.064–0.419) <0.001
Data are presented as n (%) for categorical variables and median (IQR) for continuous variables. Obesity was defined as a body mass index >−30 kg/m
2. Characteristics were
compared between the controls and cases using chi-squared test or Fisher’s exact test for categorical variables, and Kruskal-Wallis test for continuous variables. Logistic
regression was computed to identify factors associated with cirrhosis or HCC. All the variables significantly associated with liver disease in a crude analysis (p < 0.05) were
further included in a multivariable model to obtain adjusted OR. The interactions between PreS2D38-55 and HBeAg-seropositivity, HBV DNA, HBsAg levels, HBV genotype, or
AFB1 exposure were examined using a likelihood ratio test by adding interaction terms in the logistic regression model. The capability of the allelic fraction to correctly
discriminate HBV-related HCC cases from people with chronic HBV infection without HCC was evaluated using the ROC curve. Its optimal cut-off was selected to maximize the
sum of sensitivity and specificity.
AFB1, aflatoxin B1; AFP, alpha-fetoprotein; ALP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate aminotransferase; GGT, gamma-glutamyltransferase;
LSM, liver stiffness measurement.
a AFB1 exposure was assessed by next-generation sequencing using the presence of TP53 R249S mutation in cell-free DNA extracted from plasma as a surrogate biomarker.Next-generation sequencing bioinformatics and statistical
analyses
For the HBV genome, signal processing and base calling were
performed with Torrent SuiteTM Software version 5.0.2. Variant
calling was obtained using Torrent Variant Caller 5.8 and
applying somatic variant frequency, including down-sampling to
coverage of 50,000 using the HBV EG0270 genome (genotype E)
as reference. Next-generation sequencing (NGS) reads are avail-
able at the NCBI Sequence Read Archive (accession number
PRJNA527947). HBV variants were filtered and highlighted using
either IGV_2.3.55 or a Python local script.
For TP53, variant calling was performed using the Needlestack
algorithm in extra-robust regression mode (Supplementary
Methods and materials). A threshold of Phred scale q values
QVAL >30 was used to call variants (QVAL = −10 log10 [q value]).Statistical analysis
Data were analysed using Stata 13.0 (StataCorp, USA). Charac-
teristics were compared between the controls and cases using
chi-square test or Fisher’s exact test for categorical variables, and
Kruskal-Wallis test for continuous variables. Logistic regressionJHEP Reports 2020was computed to identify factors associated with cirrhosis or
HCC. All the variables significantly associated with liver disease
in a crude analysis (p <0.05) were further included in a
multivariable model to obtain adjusted odds ratio (OR). The in-
teractions between preS2D38–55 and HBeAg seropositivity, HBV
DNA, HBsAg levels, HBV genotype, or AFB1 exposure were
examined using a likelihood ratio test by adding interaction
terms in the logistic regression model.
The capability of the allelic fraction to correctly discriminate
HBV-related HCC cases from people with chronic HBV infection
without HCC was evaluated using the receiver operating
characteristic (ROC) curve. Its optimal cut-off was selected to
maximise the sum of sensitivity and specificity.Results
Study population
In this study, 302 patients were enrolled: 211 controls and 91
cases (56 individuals with cirrhosis and 35 HCC cases). The de-
mographic and clinical characteristics are presented in Table 1.
The majority were men: 74% in controls, 84% in cirrhosis cases,3vol. 2 j 100144
Table 2. Factors associated with HBV-related cirrhosis and/or HCC.
Variables
Cirrhosis HCC
Crude ORs Adjusted ORsa Crude ORs Adjusted ORsb
OR (95% CI) p value OR (95% CI) p value OR (95% CI) p value OR (95% CI) p value
Gender
Women 1.0 0.1 1.0 0.8
Men 1.8 (0.8–4.0) 0.9 (0.4–1.9)
Age (OR per unit increase) 1.0 (1.0–1.0) 0.7 1.1 (1.0–1.1) 0.01 1.0 (0.9–1.1) 0.2
HBeAg
Negative 1.0 <0.001 1.0 0.04 1.0 <0.001 1.0 0.04
Positive 4.8 (2.3–10.1) 3.2 (1.0–10.5) 7.1 (3.1–16.4) 5.4 (1.1–26.8)
HBV DNA (IU/ml)c
<2,000 1.0 <0.001 1.0 0.1 1.0 <0.001 1.0 0.002
2,000–106 3.2 (1.6–6.4) 1.5 (0.6–3.4) 4.9 (2.1–11.7) 6.3 (1.5–26.4)
>−10
6 4.8 (2.0–11.5) 2.9 (0.8–11.5) 8.8 (3.2–23.9) 15.9 (2.6–97.3)
HBsAg (IU/ml)
<10,000 1.0 <0.001 1.0 <0.001 1.0 <0.001 1.0 0.01
>−10,000 0.2 (0.1–0.3) 0.1 (0.1–0.3) 0.2 (0.1–0.5) 0.1 (0.1–0.6)
Genotype
E 1.0 0.7 1.0 <0.001 1.0 0.02
A 1.2 (0.5–2.9) 4.9 (2.1–11.3) 5.2 (1.4–19.7)
PreS2D38–55
Negative 1.0 0.002 1.0 0.09 1.0 <0.001 1.0 0.03
Positive 2.7 (1.4–5.1) 1.9 (0.9–4.2) 4.9 (2.3–10.4) 3.3 (1.1–9.7)
Anti-HDV
Negative 1.0 0.01 1.0 0.04 1.0 0.001 1.0 0.002
Positive 16.4 (1.8–149.8) 15.5 (1.1–219.7) 41.8 (4.7-372.3) 135.7 (5.9–3,124.3)
Anti-HIV
Negative 1.0 0.5 1.0 n.a.
Positive 1.9 (0.3–10.7) n.a.
AFB1 exposured
No 1.0 0.4 1.0 0.01
Yes 1.6 (0.6–4.2) 5.0 (1.5–17.2)
AFB1, aflatoxin B1; n.a., not applicable; OR, odds ratio.
a Adjusted for HBeAg, HBV DNA levels, HBsAg levels, preS2D38–55, and anti-HDV.
b Adjusted for age, HBeAg, HBV DNA levels, HBsAg levels, HBV genotype, preS2D38–55, and anti-HDV.
c p values are based on a test for trend.
d AFB1 exposure was evaluated in a subset of study participants and is not included in the multivariable analysis.
Research Articleand 71% in HCC cases. Median viral load (inter-quartile range
[IQR]; log10 IU/ml) and HBeAg positivity were 2.7 (2.2–3.3) and
8.5% in the control group, 4.0 (2.3–5.9) and 31% in cirrhosis cases,
and 5.2 (3.2–6.3) and 40% in HCC cases, respectively. Age, median
LSM, median liver function test levels, and serum AFP levels were
higher in cases than in the control group (p <0.001).
Risk factors of liver disease
HBeAg seropositivity was significantly associated with liver dis-
ease severity; adjusted OR 3.2 (95% CI 1.0–10.5; p = 0.04) for
cirrhosis and 5.4 (95% CI 1.1–26.8; p = 0.04) for HCC (Table 2).
Similarly, after adjusting for confounding factors, high viral loads
were significantly associated with HCC: compared with patients
with low viral load (<2,000 IU/ml), the ORs were 6.3 (95% CI
1.5–26.4) for 2,000–106 IU/ml and 15.9 (95% CI 2.6–97.3) for >−10
6
IU/ml. However, no association was observed between viral load
level and cirrhosis in an adjusted analysis (Table 2). Controls had
higher median HBsAg levels (4.1 log10 IU/ml; IQR 3.8–4.4) than
cirrhosis (3.7; IQR 3.3–3.9) or HCC cases (3.6; IQR 3.2–4.0)
(p <0.001) (Table 1). HBsAg levels <4.0 log10 IU/ml were
associated with an increased risk of cirrhosis and HCC (adjusted
p <0.001 and p = 0.01, respectively; Table 2).
The association of other known risk factors with liver disease
severity was examined. Alcohol consumption and coinfection
with HIV were relatively rare in this population (Table 1), and no
association was observed probably owing to the lack of statisticalJHEP Reports 2020power. HCV coinfection was more frequent in liver disease cases:
0% in control group, 4% in cirrhosis cases, and 9% in HCC cases
(p = 0.001) (Table 1). Nevertheless, logistic regression was not
performed to assess the effect of HCV because of the small
number of coinfected patients. Additionally, in this HBsAg-
positive population, coinfection with HDV, although infrequent
(10/302), was significantly associated with an increased risk of
both cirrhosis (adjusted OR 15.5; 95% CI 1.1–219.7) and HCC
(adjusted OR 135.7; 95% CI 5.9–3,124.3) (Table 2).
AFB1 exposure was evaluated using a surrogate biomarker in
a subset of participants (74 controls, 30 cirrhosis cases, and 13
HCC cases) and found in 54% of HCC cases, 27% of cirrhosis cases,
and 19% of HBsAg-positive controls (p = 0.03) (Table 1). AFB1
exposure was significantly associated with HCC risk (crude OR
5.0; 95% CI 1.5–17.2) (Table 2). Of note, no significant difference
was observed in the distribution of age, sex, alanine trans-
aminase, and viral load levels between those with or without
AFB1 assessment (data not shown). Interestingly, the median
allelic fraction in those positive for this AFB1-associated TP53
mutation was significantly higher in HCC cases than controls
(Table 1). We assessed the performance of the allelic fraction
to discriminate between those with HCC and without (HBsAg-
positive controls and cirrhosis cases), and found an area under
the ROC curve of 0.82 (95% CI 0.71–0.93) with a sensitivity
of 76.9% and specificity of 75.0% at a cut-off level of 0.0002
(Fig. 1).4vol. 2 j 100144
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Fig. 1. Performance of allelic fraction to discriminate HCC cases from non-HCC cases. ROC curve for the allelic fraction to discriminate between HCC cases
(n = 13) and those without HCC (n = 104, including 74 controls and 30 cirrhosis cases) and performance assessment. AUROC, area under the receiver operating
characteristic curve; ROC, receiver operating characteristic.HBV genetic variability
Two HBV genotypes, as assessed by S region sequencing, were
detected in the study population: 85% (256/302) were genotype
E and 14% (42/302) were genotype Awith, in addition, 1% (4/302)
A/E recombinants. Three recombinants had an A genotype
N-terminal and an E genotype C-terminal, and one N- and
C-terminals corresponding to the E genotype and a section be-
tween corresponding to the A genotype (see Fig. S1; Fig. 2). The
prevalence of genotype A was 34% in HCC cases, 12% in cirrhosis
cases, and 11% in controls (Table 1). A significant association was
observed between genotype A (vs. E) and HCC (adjusted OR 5.2;
95% CI 1.4–19.7), but not with cirrhosis (Table 2). The distribution
of covariates by each genotype in the control group is presented
in Table 3. Genotype A was associated with a family history of
liver cancer (p = 0.005) and low HBsAg levels (p <0.001), but no
association was observed with other covariates.
Multiple sequence alignments revealed a higher frequency of
preS1/preS2/S gene deletions in HCC cases (57%) than in cirrhosis
cases (43%) or control groups (25%) (p <0.001) (Table 1). The vast
majority were located in the preS2 domain (84.4%; n = 82/96)
(Fig. 3). These genotype-independent deletions were predomi-
nantly in-frame leading to 12, 15, or 18 bp (53%; n = 51/96). Losses
clustered around nucleotides 38–55 (D38–55), resulting in the
absence of up to 6 amino acids, but, as seen in the sequence logo,
the amino acid sequence 3ʹ to the deletion is conserved (Fig. 3).
This mutation profile, taken together with its high atypical
prevalence in controls (n = 41/211; 20%; Table 1), led to further
phylogenetic analyses that showed that preS2D38–55 was spread
amongst the inferred tree (Fig. 2). This would suggest that its
carriagewas not a consequence of infection by a uniqueHBV strain,
but more likely arises independently andmultiple times during or
after the initial infection of different hosts. Of the 4 A/E recombi-
nant genotypes detected, 3 were from HCC cases and 1 from a
cirrhosis case, and all carried preS2D38–55 (Table 1). Despite the
small sample size, shared recombination break points were
observed: twice between nucleotides 146 and 193.5, at nucleotide
2,891, and between nucleotides 2,897 and 3,035 (Fig. S2).
The degree of coexistence of variant and WT populations and
the quasi-species was assessed using NGS in 9 randomly selected
samples identified as either WT or preS2D38–55 by Sanger
sequencing. As shown for 3 representative examples (Fig. S3), theJHEP Reports 2020WT samples had a constant level of reads in the preS2 domain;
by contrast, all those defined as preS2D38–55 showed the
coexistence of mutant and WT sequences.
Factors associated with the presence of preS2D38–55
The presence of the preS2D38–55 hotspot mutation was not
associated with any of the demographic, lifestyle, or virological
factors in the control group (Table 3). However, it was marginally
associated with an increased risk of cirrhosis (adjusted OR 1.9;
95% CI 0.9–4.2) and significantly with HCC risk (adjusted OR 3.3;
95% CI 1.1–9.7) (Table 2). AFB1 exposure was not associated with
preS2D38–55 carriage or HBV genotype in the HBsAg-positive
controls (Table 3; Fig. S4A).
Joint effects between preS2D38–55 and the other risk factors
The interaction was examined between the effects of
preS2D38–55 and each of the following HCC risk factors: HBeAg
seropositivity, viral load, HBsAg, HBV genotype, and AFB1
exposure (Table 4). HDV was not assessed because of the small
number of coinfected patients. There was no evidence of
interaction between the effects of preS2D38–55 and HBsAg
levels (p = 0.6) or preS2D38–55 and AFB1 exposure (p = 0.9) on
HCC risk, supporting that these effects combine multiplicatively.
Although the test for heterogeneity was not statistically signifi-
cant, the joint effect on HCC was more than multiplicative
between the preS2D38–55 carriage and HBeAg seropositivity
(p = 0.1) and the preS2D38–55 carriage and viral load levels
(p = 0.1). By contrast, there was strong evidence of the interaction
between the effects of preS2D38–55 and viral genotype on HCC
(p <0.01). Compared with the reference group with the lowest
HCC risk (genotype E/deletion[−]), the ORs were 8.4 (95% CI
3.1–22.7) in genotype E/deletion(+), 12.4 (95% CI 4.1–37.7)
in genotype A/deletion(−), and 9.4 (95% CI 2.0–44.4) in genotype
A/deletion(+). These dissimilarities suggest that preS2D38–55 is
associated with an increased HCC risk in patients infected with
genotype E, but not in those infected with genotype A. However,
because of the low frequency of genotype A carriers, this dif-
ferential effect needs to be confirmed in a larger cohort. In
addition, a multiplicative effect on HCC risk was seen, albeit with
a wide CI interval, between the preS2D38–55 carriage and AFB1
exposure with a 29-fold (95% CI 3.7–230.4) increased risk5vol. 2 j 100144
Tree scale: 0.01
Fig. 2. Phylogenetic tree of HBV preS2 region. Phylogenetic tree based on the HBV S gene sequences shows that genotype E was the most frequent (red),
followed by genotype A (blue), and that 4 recombinants were detected (green). Recombinant sequences were cut at the break point and analysed (Fig. S2). The
sequences containing preS2D38–55 (dots) are spread amongst the tree. The clinical status of patients is indicated by the outer striped ring: light pink, chronic
carriers; pink, liver cirrhosis; red, HCC. Numbers at branches correspond to bootstrap values higher than 80%. The scale represents the average number of
substitutions per site.
Research Articleobserved compared with either the deletion (5.5-fold) or AFB1
(6.0-fold) exposure alone (Table 4).Discussion
This study has, for the first time, investigated the association
between HBV genetic diversity and liver disease severity in a
West African population exposed to the African environment.
In terms of virological factors, HBV genotype A, a minor ge-
notype in West Africa, was significantly associated with HCC riskJHEP Reports 2020in The Gambia (OR 5.2 [1.3–21.0]). This is in line with our pre-
vious longitudinal study in The Gambia that showed an associ-
ation between genotype A and significant liver fibrosis.28 In
southern Africa, a study estimated that patients infected with
HBV genotype A had a significantly higher HCC risk (risk ratio
4.5), which occurred 6.5 years earlier as compared to non-
genotype A-infected patients.29
Our study also found that the preS2D38–55 variants are
associated with an increased HCC risk in those infected with
genotype E, despite genotype E carriers being at lower risk of6vol. 2 j 100144
Table 3. Characteristics of HBsAg-positive controls by the presence of preS2D38–55 deletions and different HBV genotypes (n = 211).
Variables
PreS2D38–55 HBV genotypes
Absent (n = 170) Present (n = 41) p value E (n = 188) A (n = 23) p value
Demographic factors
Gender
Women 47 (85) 8 (15) 0.3 49 (89) 6 (11) 0.9
Men 123 (79) 33 (21) 139 (89) 17 (11)
Age (years)
<40 134 (82) 30 (18) 0.4 145 (88) 19 (12) 0.6
>−40 36 (77) 11 (23) 43 (91) 4 (9)
Birth place
Rural 114 (78) 32 (22) 0.2 131 (90) 15 (10) 0.7
Urban 56 (86) 9 (14) 57 (88) 8 (12)
Family history of liver cancer
No 161 (81) 39 (19) 0.9 181 (90) 19 (10) 0.005
Yes 9 (82) 2 (18) 7 (64) 4 (36)
Lifestyle factors
Alcohol intake
Never 162 (81) 38 (19) 0.5 180 (90) 20 (10) 0.07
Ever 8 (73) 3 (27) 8 (73) 3 (27)
AFB1 exposure
No 44 (73) 16 (27) 0.7 54 (90) 6 (10) 0.2
Yes 11 (79) 3 (21) 14 (100) 0
Virological factors
HBeAg seropositivity
Negative 155 (80) 38 (20) 0.8 171 (89) 22 (11) 0.4
Positive 15 (83) 3 (17) 17 (94) 1 (6)
HBV DNA (IU/ml)
<2,000 125 (81) 30 (19) 0.9 137 (88) 18 (12) 0.8
2,000–106 32 (80) 8 (20) 36 (90) 4 (10)
>−10
6 13 (81) 3 (19) 15 (94) 1 (6)
HBsAg levels (IU/ml)
<10,000 46 (74) 16 (26) 0.3 48 (77) 14 (23) <0.001
>−10,000 87 (81) 21 (19) 103 (95) 5 (5)
Genotype
E 154 (82) 34 (18) 0.2 n.a. n.a.
A 16 (70) 7 (30) n.a. n.a.
Anti-HCV
Negative 170 (81) 41 (19) n.a. 188 (89) 23 (11) n.a.
Positive 0 0 0 0
Anti-HDV
Negative 168 (80) 41 (20) 0.6 187 (89) 22 (11) 0.7
Positive 1 (100) 0 1 (100) 0
Anti-HIV
Negative 165 (80) 41 (20) 0.3 184 (89) 22 (11) 0.4
Positive 4 (100) 0 3 (75) 1 (25)
Data are presented as n (%).
AFB1, aflatoxin B1; n.a., not applicable.HCC than genotype A patients. PreS deletions have been exten-
sively described in Asian cohorts,30–32 mainly in HBV genotypes
B and C. A systematic literature review and meta-analysis per-
formed on 109 such studies and including 1,511 patients has also
reported an association between preS2 variants and HCC with an
overall OR of 3.0 (2.3–3.9).33 However, a clear distinction be-
tween the studies is the location of the preS deletion. In these
Asian cohorts, they are scattered throughout the preS re-
gion,30–33 whereas in the PROLIFICA cohort a deletion hotspot
was found specifically in the preS2 domain. The phylogenetic
tree based on sequences from the study population suggests that
the mutated viruses arise independently many times and are not
a unique viral strain. This aspect has not been investigated in
other populations and clearly needs to be addressed in future
studies.
The finding of the preS2D38–55 deletion hotspot raises a
number of questions:JHEP Reports 2020 its origin and whether it is a consequence of the presence or
processing of DNA adducts on the viral genome caused by
exposure to an environmental mutagen;
 if the deleted virus has a selective advantage in the Gambian
environment; and
 the cellular consequences of the circulating mutant virus.
AFB1 is one candidate mutagen that has been shown to
interact with HBV DNA.34 Based on the p53R249S mutation
analysis in cfDNA from individuals for whom adequate plasma
samples were available, a high proportion of the study popula-
tion (25%) has been exposed to AFB1, and this exposure was
significantly associated with HCC risk. In addition, we noted that
the median allelic fraction in those positive for this AFB1-
associated TP53 mutation was significantly higher in HCC cases
than in controls. The p53R249S allelic fraction is an integrated
marker of both past AFB1 exposure and the presence of a tumour7vol. 2 j 100144
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Fig. 3. Variants detected in HBV surface (S) genes, their positions, and prevalence. As shown, 96/302 S gene sequences had mutations localised for the vast
majority (82/96) in the preS2 domain at positions 38–55 (EcoRI nomenclature). Of these, 53% lost 12, 15, or 18 bp (shades of orange, green, and blue, respectively).
Corresponding amino acid changes are shown using a sequence logo. The thickness of the bar reflects the frequency of the deletion. The other mutations (14/96)
were localised elsewhere in the S genes. n.a., not applicable; WT, wild type.
Table 4. Joint effect of preS2D38–55 and HBeAg seropositivity, viral load, HBsAg levels, HBV genotype, and AFB1 exposure, on HCC risk.
Variables Controls (n = 211) HCC cases (n = 35) OR (95% CI) p value for heterogeneity
HBeAg/preS2D38–55 0.1
(−)/(−) 155 (74) 12 (34) 1.0
(−)/(+) 38 (18) 9 (26) 3.1 (1.2–7.8)
(+)/(−) 15 (7) 4 (11) 3.4 (1.0–12.0)
(+)/(+) 3 (1) 10 (29) 43.1 (10.4–177.7)
HBV DNA/preS2D38–55 0.1
<2,000/(−) 125 (59) 8 (23) 1.0
<2,000/(+) 30 (14) 3 (9) 1.6 (0.4–6.2)
>−2,000/(−) 45 (22) 8 (23) 2.8 (1.0–7.8)
>−2,000/(+) 11 (5) 16 (45) 22.7 (8.0–64.9)
HBsAg/preS2D38–55 0.6
>−10,000/(−) 87 (51) 4 (12) 1.0
>−10,000/(+) 21 (12) 5 (14) 5.2 (1.3–21.0)
<10,000/(−) 46 (27) 12 (34) 5.7 (1.7–18.6)
<10,000/(+) 16 (10) 14 (40) 19.0 (5.5–65.3)
Genotype/preS2D38–55 <0.01
E/(−) 154 (73) 7 (22) 1.0
E/(+) 34 (16) 13 (41) 8.4 (3.1–22.7)
A/(−) 16 (8) 9 (28) 12.4 (4.1–37.7)
A/(+) 7 (3) 9 (9) 9.4 (2.0–44.4)
AFB1/preS2D38–55
(−)/(−) 44 (59) 2 (15) 1.0 0.9
(−)/(+) 16 (22) 4 (31) 5.5 (0.9–33.0)
(+)/(−) 11 (15) 3 (23) 6.0 (0.9–40.4)
(+)/(+) 3 (4) 4 (31) 29.3 (3.7–230.4)
AFB1, aflatoxin B1; OR, odds ratio.
Research Articlecarrying this mutation, and indicative of HCC. The sensitivity and
specificity of the technique used in this study to detect mutant
p53 alleles are comparable with those obtained using another
highly sensitive technology, the droplet digital PCR,35 and high-
light their potential in assessing this biomarker in liquid biopsy
studies for identifying and confirming HCC status as reviewed in
1 study.36 Moreover, AFB1 exposure could contribute to the low
viral load observed in chronic HBV carriers in The Gambia as
in vitro AFB1 exposure has been reported to reduce HBVJHEP Reports 2020replication.34 In addition, we report for the first time a potential
multiplicative effect of AFB1 exposure and HBV preS2D38–55
carriage on HCC risk, clearly highlighting the impact of this
environmental carcinogen.
In terms of possible impacts, the preS2D38–55 variant did
not affect viral replication as similar viral loads, median HBsAg
levels, and HBeAg prevalence were found in individuals infected
with the preS2D38–55 or WT virus (Fig. S4B–D). This is likely
caused by a cohabitation of the WT HBV with the preS2D38–558vol. 2 j 100144
form within hepatocytes. Under such a coexistence, the WT viral
DNA could compensate the variants with full-length surface
proteins, which in turn allows the release of variant surface
protein encoding virions, as described previously.37 Our NGS
data lend support to this situation and raise an important
caveat: using Sanger sequencing, the prevalence and proportion
of preS2D38–55 in populations are likely underestimated
(Fig. S3).
Finally, previous literature suggests that preS2 deletions
modulate cellular processes with a potential impact on liver
disease. In addition to reducing envelope protein levels and
favouring their retention in the endoplasmic reticulum (ER)
resulting in ER stress,38 similar preS2 mutant proteins interact
with importin a1, a key nuclear transportation factor. This results
in reduced nuclear Nijmegen breakage syndrome 1 (NBS1) pro-
tein levels and defects in NBS1-mediated homologous recombi-
nation that could contribute to genetic instability.39 Other
reports identified preS2 variants as associated with ground glass
hepatocytes, which might be associated with preneoplastic le-
sions in chronic HBV infection.38–41 Further in vitro studies are
needed to fully decipher the molecular mechanisms generating
this mutation, its cellular consequences, and whether this quasi-
species context of preS2 deletions and WT species could explain
the persistence of the variant that would otherwise be negatively
selected owing to its altered surface proteins.
Our study has limitations. Firstly, it was conducted in a cross-
sectional manner, and therefore care must be taken to interpret
the association between virological factors and liver disease
severity. A longitudinal cohort study is underway to confirm
these associations observed here. Secondly, the number of studyJHEP Reports 2020participants, particularly those with HCC, was limited, and
numerous variables were assessed for their potential associa-
tions with HCC. This might have led to a lack of statistical power
to identify associations of some of the variables, and also might
have resulted in generating ‘chance findings’. It was indeed
difficult to recruit and obtain blood samples from patients with
end-stage liver disease. Nevertheless, the strength of association
observed in several analyses in this study supports the robust-
ness of the study findings. Thirdly, because of limited access
to liver biopsy in this resource-limited setting, wewere unable to
distinguish between HCC cases with and without cirrhosis, or to
report their degree of fibrosis. In addition, as patients with HCC
in SSA present at advanced stages, we were unable to recruit
individuals with early small tumours, and all patients had
tumours >5 cm (data not shown). Finally, whilst our partial
HBV sequences (surface genes) are sufficient for genotyping,3,4
they are not for sub-genotyping as numerous misclassifications
will arise,42–44 and this issue needs to be resolved in future
studies.
In conclusion, this study, which provides novel findings on
HBV quasi-species and its impact on liver disease severity in The
Gambia, identified the HBV preS2D38–55 variant as a strong
independent risk factor and a biomarker for HCC in West African
patients. Future studies need to use highly sensitive sequencing
technologies to be able to fully validate this risk factor and
address the mechanistic impact of its carriage on liver disease.
This could help improve our understanding and the significance
of the full virological profile of patients with chronic HBV
infection to establish appropriate screening criteria and treat-
ment strategies in such high-risk communities.Abbreviations
AFB1, aflatoxin B1; AFP, alpha-fetoprotein; ER, endoplasmic reticulum;
LSM, liver stiffness measurement; NBS1, Nijmegen breakage syndrome 1;
NGS, next-generation sequencing; OR, odds ratio; PROLIFICA, Prevention
of Liver Fibrosis and Cancer in Africa; ROC, receiver operating character-
istic; SSA, sub-Saharan Africa; WT, wild type.
Financial support
European Commission (FP7); Agence Nationale de Recherches sur le Sida
et les Hepatites Virales (12357); the ARC Santé from the Region Auvergne
Rhône-Alpes; NIHR Imperial Biomedical Research Centre.
Conflicts of interest
The authors declare no conflicts of interest that pertain to this work.
Please refer to the accompanying ICMJE disclosure forms for further
details.
Authors’ contributions
DC, SG, YS, ML, JH, and IC drafted the paper, and all the authors reviewed
and approved it. IC, ML, MT, MM, and FZ designed the study. ML, YS, NR,
and GN recruited the patients. DC, SG, AD, CG, and NK-ND carried out
laboratory analyses. YS carried out statistical analysis. PSG and CB-A
carried out phylogenetic analyses. SA, GD, and CV carried out next-
generation sequencing (NGS) analyses. FLC-K designed NGS TP53 assay
and supervised these analyses. JH, IC, MM, NR, and GN supported the
conduct of the study.
Acknowledgements
The authors thank Emilie Guérin and Rémi Moulinas from the genomic
platform GenoLim at Limoges University Hospital for next-generation
sequencing and analysis, and Christophe Combet for his expertise on
HBV genotypes.Supplementary data
Supplementary data to this article can be found online at https://doi.org/
10.1016/j.jhepr.2020.100144.
References
Author names in bold designate shared co-first authorship
[1] Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of
worldwide prevalence of chronic hepatitis B virus infection: a systematic
review of data published between 1965 and 2013. Lancet 2015;386:1546–
1555.
[2] Maucort-Boulch D, de Martel C, Franceschi S, Plummer M. Fraction and
incidence of liver cancer attributable to hepatitis B and C viruses world-
wide: liver cancer attributable to hepatitis viruses worldwide. Int J Cancer
2018;142:2471–2477.
[3] Norder H, Couroucé A-M, Coursaget P, Echevarria JM, Lee S-D,
Mushahwar IK, et al. Genetic diversity of hepatitis B virus strains derived
worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology
2004;47:289–309.
[4] Hussain M, Chu C-J, Sablon E, Lok ASF. Rapid and sensitive assays for
determination of hepatitis B virus (HBV) genotypes and detection of
HBV precore and core promoter variants. J Clin Microbiol 2003;41:3699–
3705.
[5] Rajoriya N, Combet C, Zoulim F, Janssen HLA. How viral genetic variants
and genotypes influence disease and treatment outcome of chronic
hepatitis B. Time for an individualised approach? J Hepatol 2017;67:1281–
1297.
[6] Hayer J, Jadeau F, Deléage G, Kay A, Zoulim F, Combet C. HBVdb: a
knowledge database for hepatitis B virus. Nucleic Acids Res
2013;41:D566–D570.
[7] Malve B, Eschlimann M, Galgey S, Fenaux H, Zoulim F, Goehringer F, et al.
Impact of deletions and mutations in hepatitis B virus envelope proteins
on serological profile and clinical evolution. Virus Res 2017;238:141–147.9vol. 2 j 100144
Research Article[8] Pollicino T, Cacciola I, Saffioti F, Raimondo G. Hepatitis B virus PreS/S gene
variants: pathobiology and clinical implications. J Hepatol 2014;61:
408–417.
[9] Wild CP, Montesano R. A model of interaction: aflatoxins and hepatitis
viruses in liver cancer aetiology and prevention. Cancer Lett
2009;286:22–28.
[10] Gouas D, Shi H, Hainaut P. The aflatoxin-induced TP53 mutation at codon
249 (R249S): biomarker of exposure, early detection and target for ther-
apy. Cancer Lett 2009;286:29–37.
[11] Mendy ME, Welzel T, Lesi OA, Hainaut P, Hall AJ, Kuniholm MH, et al.
Hepatitis B viral load and risk for liver cirrhosis and hepatocellular car-
cinoma in the Gambia, West Africa. J Viral Hepat 2010;17:115–122.
[12] Kirk GD, Lesi OA, Mendy M, Akano AO, Sam O, Goedert JJ, et al. The
Gambia liver cancer study: infection with hepatitis B and C and the risk of
hepatocellular carcinoma in West Africa. Hepatology 2004;39:211–219.
[13] Mahale P, Aka P, Chen X, Pfeiffer RM, Liu P, Groover S, et al. Hepatitis D
virus infection, cirrhosis and hepatocellular carcinoma in the Gambia.
J Viral Hepat 2019;26:738–749.
[14] Kirk GD, Lesi OA, Mendy M, Szymañska K, Whittle H, Goedert JJ, et al.
249(ser) TP53 mutation in plasma DNA, hepatitis B viral infection, and
risk of hepatocellular carcinoma. Oncogene 2005;24:5858–5867.
[15] Lemoine M, Shimakawa Y, Njie R, Taal M, Ndow G, Chemin I, et al.
Acceptability and feasibility of a screen-and-treat programme for hepa-
titis B virus infection in the Gambia: the Prevention of Liver Fibrosis and
Cancer in Africa (PROLIFICA) study. Lancet Glob Health 2016;4:e559–e567.
[16] Shimakawa Y, Lemoine M, Bottomley C, Njai HF, Ndow G, Jatta A, et al.
Birth order and risk of hepatocellular carcinoma in chronic carriers of
hepatitis B virus: a case-control study in the Gambia. Liver Int
2015;35:2318–2326.
[17] Lemoine M, Shimakawa Y, Nayagam S, Khalil M, Suso P, Lloyd J, et al. The
gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts signifi-
cant liver fibrosis and cirrhosis in patients with chronic HBV infection in
West Africa. Gut 2016;65:1369–1376.
[18] Ghosh S, Banerjee P, RoyChoudhury A, Sarkar S, Ghosh A, Santra A, et al.
Unique hepatitis B virus subgenotype in a primitive tribal community in
eastern India. J Clin Microbiol 2010;48:4063–4071.
[19] Ghosh S, Banerjee P, Deny P, Mondal RK, Nandi M, RoyChoudhury A, et al.
New HBV subgenotype D9, a novel D/C recombinant, identified in patients
with chronic HBeAg-negative infection in eastern India. J Viral Hepat
2013;20:209–218.
[20] Madeira F, Park YM, Lee J, Buso N, Gur T, Madhusoodanan N, et al. The
EMBL-EBI search and sequence analysis tools APIs in 2019. Nucleic Acids
Res 2019;47:W636–W641.
[21] Crooks GE, Hon G, Chandonia J-M, Brenner SE. WebLogo: a sequence logo
generator. Genome Res 2004;14:1188–1190.
[22] Schultz A-K, Bulla I, Abdou-Chekaraou M, Gordien E, Morgenstern B,
Zoulim F, et al. jpHMM: recombination analysis in viruses with circular
genomes such as the hepatitis B virus. Nucleic Acids Res 2012;40:W193–
W198.
[23] Ranwez V, Harispe S, Delsuc F, Douzery EJP. MACSE: multiple Alignment
of Coding SEquences accounting for frameshifts and stop codons. PLoS
One 2011;6:e22594.
[24] Criscuolo A, Gribaldo S. BMGE (Block Mapping and Gathering with En-
tropy): a new software for selection of phylogenetic informative regions
from multiple sequence alignments. BMC Evol Biol 2010;10:210.
[25] Guindon S, Dufayard J-F, Lefort V, AnisimovaM, HordijkW, Gascuel O. New
algorithms and methods to estimate maximum-likelihood phylogenies:
assessing the performance of PhyML 3.0. Syst Biol 2010;59:307–321.JHEP Reports 2020[26] Kalyaanamoorthy S, Minh BQ, Wong TKF, von Haeseler A, Jermiin LS.
ModelFinder: fast model selection for accurate phylogenetic estimates.
Nat Methods 2017;14:587–589.
[27] Letunic I, Bork P. Interactive Tree of Life (iTOL) v3: an online tool for the
display and annotation of phylogenetic and other trees. Nucleic Acids Res
2016;44:W242–W245.
[28] Shimakawa Y, Lemoine M, Njai HF, Bottomley C, Ndow G, Goldin RD,
et al. Natural history of chronic HBV infection in West Africa: a longitu-
dinal population-based study from the Gambia. Gut 2016;65:2007–2016.
[29] Kew MC, Kramvis A, Yu MC, Arakawa K, Hodkinson J. Increased hep-
atocarcinogenic potential of hepatitis B virus genotype A in Bantu-
speaking sub-Saharan Africans. J Med Virol 2005;75:513–521.
[30] Chen B, Liu C, Jow G, Chen P, Kao J, Chen D. High prevalence and mapping
of pre-S deletion in hepatitis B virus carriers with progressive liver dis-
eases. Gastroenterology 2006;130:1153–1168.
[31] Yeung P, Wong DK-H, Lai C-L, Fung J, Seto W-K, Yuen M-F. Association of
hepatitis B virus pre-S deletions with the development of hepatocellular
carcinoma in chronic hepatitis B. J Infect Dis 2011;203:646–654.
[32] Chen B-F. Hepatitis B virus pre-S/S variants in liver diseases. World J
Gastroenterol 2018;24:1507–1520.
[33] Liu W-C, Wu I-C, Lee Y-C, Lin C-P, Cheng J-H, Lin Y-J, et al. Hepatocellular
carcinoma-associated single-nucleotide variants and deletions identified
by the use of genome-wide high-throughput analysis of hepatitis B virus.
J Pathol 2017;243:176–192.
[34] Lereau M, Gouas D, Villar S, Besaratinia A, Hautefeuille A, Berthillon P,
et al. Interactions between hepatitis B virus and aflatoxin B1: effects on
p53 induction in HepaRG cells. J Gen Virol 2012;93:640–650.
[35] Marchio A, Amougou Atsama M, Béré A, Komas N-P, Noah Noah D,
Atangana PJA, et al. Droplet digital PCR detects high rate of TP53 R249S
mutants in cell-free DNA of middle African patients with hepatocellular
carcinoma. Clin Exp Med 2018;18:421–431.
[36] Su Y-H, Kim AK, Jain S. Liquid biopsies for hepatocellular carcinoma.
Transl Res 2018;201:84–97.
[37] Gerken G, Kremsdorf D, Capel F, Petit MA, Dauguet C, Manns MP, et al.
Hepatitis B defective virus with rearrangements in the PreS gene during
chronic HBV infection. Virology 1991;183:555–565.
[38] Hsieh Y-H, Su I-J, Wang H-C, Chang W-W, Lei H-Y, Lai M-D, et al. Pre-S
mutant surface antigens in chronic hepatitis B virus infection induce
oxidative stress and DNA damage. Carcinogenesis 2004;25:2023–2032.
[39] Hsieh Y-H, Chang Y-Y, Su I-J, Yen C-J, Liu Y-R, Liu R-J, et al. Hepatitis B virus
pre-S2 mutant large surface protein inhibits DNA double-strand break
repair and leads to genome instability in hepatocarcinogenesis. J Pathol
2015;236:337–347.
[40] Su I-J, Wang H-C, Wu H-C, Huang W-Y. Ground glass hepatocytes contain
pre-S mutants and represent preneoplastic lesions in chronic hepatitis B
virus infection. J Gastroenterol Hepatol 2008;23:1169–1174.
[41] Su I-J, Wang LH-C, Hsieh W-C, Wu H-C, Teng C-F, Tsai H-W, et al. The
emerging role of hepatitis B virus pre-S2 deletion mutant proteins in HBV
tumorigenesis. J Biomed Sci 2014;21:98.
[42] Jia L, Hu F, Li H, Li L, Tang X, Liu Y, et al. Characterization of small genomic
regions of the hepatitis B virus should be performed with more caution.
Virol J 2018;15:188.
[43] Pourkarim MR, Amini-Bavil-Olyaee S, Lemey P, Maes P, Van Ranst M. Are
hepatitis B virus “subgenotypes” defined accurately? J Clin Virol
2010;47:356–360.
[44] McNaughton AL, Revill PA, Littlejohn M, Matthews PC, Ansari MA. Anal-
ysis of genomic-length HBV sequences to determine genotype and
subgenotype reference sequences. J Gen Virol 2020;101:271–283.10vol. 2 j 100144
